Pfizer-BioNTech's COVID-19 Booster Study Shows Robust Efficacy

Pfizer Inc PFE and BioNTech SE BNTX announced topline results from a Phase 3 trial evaluating the efficacy and safety of a 30-µg booster dose of its COVID-19 vaccine.
Related: Pfizer/BioNTech COVID-19 Boosters For Seniors, Certain Vulnerable Adults Coming Soon - CDC Panel Recommends.
Data from a large study showed that the booster dose restored efficacy to 95.6% against the virus, including the Delta variant.
The companies said the trial was not peer-reviewed, tested 10,000 participants aged 16 and older, and found that the booster shot had a favorable safety profile.
There were 5 cases of COVID-19 in the boosted group and 109 cases in the non-boosted group during the study period.
Related: Oxford-Led Study Shows Efficacy Of COVID-19 Vaccines Dwindles Over Time Against Delta Variant.
The Companies said that the median time between the second dose and the booster shot or the placebo in the study was around 11 months.
The median age of the participants was 53 years, with 55.5% of participants between 16 and 55 years, and 23.3% at 65 years or older.
Related: FDA Approves 'Mix And Match' COVID-19 Shots.
Price Action: PFE shares are down 0.71% at $42.49, BNTX stock is up 5.27% at $283.4, during the market session on the last check Thursday.
Photo by x3 from Pixabay